The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

2009691 citationsReviewbronze Open Access

Authors

Giorgio V. Scagliotti · Ospedale San Luigi Gonzaga

Nasser H. Hanna · Indiana University – Purdue University Indianapolis

Frank V. Fossella · The University of Texas MD Anderson Cancer Center

Katherine P. Sugarman · Eli Lilly (United States)

J. Blatter · Eli Lilly (United States)

Patrick Peterson · Eli Lilly (United States)

Lorinda Simms

Abstract

The consistency of these results across studies confirms the predictive effect of histology for pemetrexed and the survival advantage for pemetrexed in patients with nonsquamous histology. These analyses suggest pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, pemetrexed may be preferable to other agents for treatment of patients with nonsquamous NSCLC.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Oncologist

Volume 14, Issue 3, pp. 253-263

DOI: 10.1634/theoncologist.2008-0232

Field-Weighted Citation Impact: 62.12